These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22214262)

  • 1. Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations.
    Diamantopoulos PT; Michael M; Benopoulou O; Bazanis E; Tzeletas G; Meletis J; Vayopoulos G; Viniou NA
    Virol J; 2012 Jan; 9():1. PubMed ID: 22214262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidne.
    Panovska-Stavridis I; Ivanovski M; Trajkova S; Pivkova-Veljanovska A; Popova-Labaceska M; Matevska-Geshovska N; Noveski P; Plaseska-Karanfilska D; Cevreska L; Dimovski AJ
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Dec; 38(3):157-162. PubMed ID: 29668469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of autoimmune and inflammatory disorders in myelodysplastic syndromes to 5-azacytidine: report of two cases and literature review.
    Wu DY; Wang J; Zhang R; Yan XJ; Gao R
    Ann Palliat Med; 2021 Aug; 10(8):9276-9280. PubMed ID: 34488413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effective azacitidine treatment for myelodysplastic syndrome transformed from essential thrombocythemia].
    Iizuka H; Yoshimi A; Yamamoto G; Masuda A; Nannya Y; Ichikawa M; Yatomi Y; Kurokawa M
    Rinsho Ketsueki; 2013 May; 54(5):468-72. PubMed ID: 23727686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of human T-cell leukemia virus and myelodysplastic syndrome in a central European population.
    Karlic H; Möstl M; Mucke H; Pavlova B; Pfeilstöcker M; Heinz R
    Cancer Res; 1997 Nov; 57(21):4718-21. PubMed ID: 9354429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of human T-lymphotropic virus type I carriers among patients with myelodysplastic syndrome refractory anemia with excess of blasts (RAEB), RAEB in transformation and acute promyelocytic leukemia.
    Inoue H; Matsushita K; Arima N; Hamada H; Uozumi K; Ozaki A; Akimoto M; Kawada H; Kukita T; Yoshimitsu M; Matsumoto T; Tei C
    Leuk Lymphoma; 2008 Feb; 49(2):315-21. PubMed ID: 18231919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune hemolytic anemia in a patient with myelodysplastic syndrome: Responding to 5-azacitidine therapy.
    Kaur J; Tuler S; Dasanu CA
    J Oncol Pharm Pract; 2021 Oct; 27(7):1775-1778. PubMed ID: 33446051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome.
    Yang Y; Zhang Q; Xu F; Chang C; Li X
    Eur J Haematol; 2012 Dec; 89(6):469-77. PubMed ID: 23005040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
    Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
    Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
    Grövdal M; Karimi M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engström LM; Kjeldsen L; Linder O; Nilsson L; Olsson A; Holm MS; Tangen JM; Wallvik J; Oberg G; Hokland P; Jacobsen SE; Porwit A; Hellström-Lindberg E
    Br J Haematol; 2010 Aug; 150(3):293-302. PubMed ID: 20497178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete response of deep neutrophilic dermatosis associated with myelodysplastic syndrome to 5-azacytidine.
    Raj K; Ho A; Creamer JD; du Vivier AW; Salisbury JR; Mufti GJ
    Br J Dermatol; 2007 May; 156(5):1039-41. PubMed ID: 17408390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral therapy promotes an inflammatory-like pattern of human T-cell lymphotropic virus type 1 (HTLV-1) replication in human immunodeficiency virus type 1/HTLV-1 co-infected individuals.
    Pomier C; Rabaaoui S; Pouliquen JF; Couppié P; El Guedj M; Nacher M; Lacoste V; Wattel E; Kazanji M; Mortreux F
    J Gen Virol; 2013 Apr; 94(Pt 4):753-757. PubMed ID: 23239567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelodysplastic syndromes and autoimmune diseases--case series and review of literature.
    Al Ustwani O; Ford LA; Sait SJ; Block AM; Barcos M; Vigil CE; Griffiths EA; Thompson JE; Wang ES; Ambrus J; Wetzler M
    Leuk Res; 2013 Aug; 37(8):894-9. PubMed ID: 23692654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Fraison JB; Mekinian A; Grignano E; Kahn JE; Arlet JB; Decaux O; Denis G; Buchdahl AL; Omouri M; Maigne G; Aouba A; Leon N; Berthier S; Liozon E; Park S; Gardin C; Lortholary O; Rossignol J; Fenaux P; Fain O; Braun T
    Leuk Res; 2016 Apr; 43():13-7. PubMed ID: 26922775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group.
    Cseh AM; Niemeyer CM; Yoshimi A; Catala A; Frühwald MC; Hasle H; van den Heuvel-Eibrink MM; Lauten M; De Moerloose B; Smith OP; Bernig T; Gruhn B; Kulozik AE; Metzler M; Olcay L; Suttorp M; Furlan I; Strahm B; Flotho C
    Br J Haematol; 2016 Mar; 172(6):930-6. PubMed ID: 26766110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group.
    Papageorgiou SG; Kotsianidis I; Kontos CK; Symeonidis A; Galanopoulos A; Hatzimichael E; Poulakidas E; Diamantopoulos P; Vassilakopoulos TP; Zikos P; Papadaki H; Bouronikou E; Panayiotidis P; Viniou NA; Pappa V
    Leuk Res; 2018 Aug; 71():55-59. PubMed ID: 30007218
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of nucleoside-based antiretroviral chemotherapy on human T cell leukaemia/lymphotropic virus type 1 (HTLV-1) infection in vitro.
    Macchi B; Balestrieri E; Mastino A
    J Antimicrob Chemother; 2003 Jun; 51(6):1327-30. PubMed ID: 12716774
    [No Abstract]   [Full Text] [Related]  

  • 18. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.
    Santini V; Fenaux P; Mufti GJ; Hellström-Lindberg E; Silverman LR; List A; Gore SD; Seymour JF; Backstrom J; Beach CL
    Eur J Haematol; 2010 Aug; 85(2):130-8. PubMed ID: 20394651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50.
    Uchida T; Hagihara M; Hua J; Inoue M
    Leuk Res; 2017 Feb; 53():35-38. PubMed ID: 28013105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.